Emergent BioSolutions Inc. 8-K Report: Key Updates & Insights for Investors

Based on the provided section of the financial report, here are the key pieces of information extracted:

Entity Information:

Company Name: Emergent BioSolutions Inc.
CIK (Central Index Key): 0001367644
State of Incorporation: Delaware (DE)
SEC File Number: 001-33137
EIN (Employer Identification Number): 14-1902018
Address: 300 Professional Drive, Gaithersburg, MD 20879
Phone Number: 240-631-3200

Report Type:

Form Type: 8-K (Current Report)
Report Date: December 12, 2024

Stock Information:

Common Stock Par Value: $0.001 per share
Ticker Symbol: EBS
Exchange: NYSE (New York Stock Exchange)

Reporting Period:

Start Date: December 12, 2024
End Date: December 12, 2024

XML and XBRL Information:

The report is formatted in XBRL (eXtensible Business Reporting Language), which is commonly used for financial data reporting.

Insights:

Emergent BioSolutions is filing an 8-K, which indicates that there may be significant events or changes to report that could impact investors or stakeholders.
The timing of the report aligns with the end of the fiscal period, suggesting it may contain information pertinent to quarterly or annual performance.
The company is publicly traded on the NYSE under the ticker EBS, making it subject to regular disclosures mandated by the SEC.
The use of XBRL indicates a commitment to transparency and adherence to regulatory standards for financial reporting.

This information could be relevant for investors, analysts, and stakeholders looking to understand the current status and operations of Emergent BioSolutions Inc.